KR20230058132A - Gpr52 조절인자 화합물 - Google Patents

Gpr52 조절인자 화합물 Download PDF

Info

Publication number
KR20230058132A
KR20230058132A KR1020237010457A KR20237010457A KR20230058132A KR 20230058132 A KR20230058132 A KR 20230058132A KR 1020237010457 A KR1020237010457 A KR 1020237010457A KR 20237010457 A KR20237010457 A KR 20237010457A KR 20230058132 A KR20230058132 A KR 20230058132A
Authority
KR
South Korea
Prior art keywords
disorder
pyridin
tetrahydro
trifluoromethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237010457A
Other languages
English (en)
Korean (ko)
Inventor
사라 조안느 버크넬
스티븐 폴 왓슨
마이클 알리스테어 오브라이언
Original Assignee
헵테얼즈 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헵테얼즈 테라퓨틱스 리미티드 filed Critical 헵테얼즈 테라퓨틱스 리미티드
Publication of KR20230058132A publication Critical patent/KR20230058132A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Amplifiers (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020237010457A 2020-08-28 2021-08-31 Gpr52 조절인자 화합물 Pending KR20230058132A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2013558.8 2020-08-28
GBGB2013558.8A GB202013558D0 (en) 2020-08-28 2020-08-28 GRP52 Modularor compounds
PCT/GB2021/052247 WO2022043714A1 (en) 2020-08-28 2021-08-31 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
KR20230058132A true KR20230058132A (ko) 2023-05-02

Family

ID=72749711

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237010457A Pending KR20230058132A (ko) 2020-08-28 2021-08-31 Gpr52 조절인자 화합물

Country Status (12)

Country Link
US (1) US20230348416A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204408A1 (cg-RX-API-DMAC7.html)
JP (1) JP7761635B6 (cg-RX-API-DMAC7.html)
KR (1) KR20230058132A (cg-RX-API-DMAC7.html)
CN (1) CN116507622B (cg-RX-API-DMAC7.html)
AU (1) AU2021330379A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023003696A2 (cg-RX-API-DMAC7.html)
CA (1) CA3193487A1 (cg-RX-API-DMAC7.html)
GB (1) GB202013558D0 (cg-RX-API-DMAC7.html)
IL (1) IL301007B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023002389A (cg-RX-API-DMAC7.html)
WO (1) WO2022043714A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
CN122555695A (zh) * 2023-11-29 2026-08-11 爱克堤欧生物科学股份有限公司 可用作kcnt1抑制剂的杂环化合物
CN121313618B (zh) * 2025-12-09 2026-07-21 杭州师范大学附属医院(杭州市第二人民医院) 丙酸在制备治疗肝豆状核变性肠肝轴紊乱的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
WO2017077280A1 (en) * 2015-11-02 2017-05-11 Sonia Lain Tetrahydroindazoles and medical uses thereof
WO2021009003A1 (en) * 2019-07-16 2021-01-21 Universität Hamburg Computer-based identification of types in the empirical sciences by tangle theory
CN114650992A (zh) * 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物

Also Published As

Publication number Publication date
CN116507622B (zh) 2026-02-24
IL301007B1 (en) 2026-04-01
IL301007A (en) 2023-05-01
WO2022043714A1 (en) 2022-03-03
US20230348416A1 (en) 2023-11-02
MX2023002389A (es) 2023-05-03
BR112023003696A2 (pt) 2023-04-04
EP4204408A1 (en) 2023-07-05
AU2021330379A1 (en) 2023-03-30
CN116507622A (zh) 2023-07-28
CA3193487A1 (en) 2022-03-03
IL301007B2 (en) 2026-08-01
JP2023539336A (ja) 2023-09-13
JP7761635B2 (ja) 2025-10-28
JP7761635B6 (ja) 2025-11-27
GB202013558D0 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
JP7761635B2 (ja) Gpr52モジュレーター化合物
JP6254075B2 (ja) カリウムチャネル遮断剤としてのアミン誘導体
JP7492597B2 (ja) Gpr52モジュレーター化合物
KR102585048B1 (ko) Jak1 선택적 억제제
WO2013131018A1 (en) Biaryl inhibitors of the sodium channel
CA3047404A1 (en) Compounds, compositions and methods of use
EP4401833B1 (en) Gpr52 modulator compounds
EP2524912A1 (en) Amine derivatives
RU2844473C1 (ru) Соединения модуляторы gpr52
HK40107480A (en) Gpr52 modulator compounds
HK40107480B (en) Gpr52 modulator compounds
HK40078521B (en) Gpr52 modulator compounds
HK40078521A (en) Gpr52 modulator compounds
KR20220098160A (ko) 아드레날린수용체 adrac2의 억제제
HK1195556A (en) Amine derivatives as potassium channel blockers
HK1195556B (en) Amine derivatives as potassium channel blockers
NZ617638B2 (en) Amine derivatives as potassium channel blockers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000